A psychiatric medication review can become a very small conversation: Are you doing okay? Any side effects? Need a refill?
That may be enough to keep a prescription moving. It is rarely enough to determine whether the medication still makes sense.
A February 2026 consensus statement from the American Society of Clinical Psychopharmacology made a useful point: the value of continuing any psychiatric medication should be reassessed periodically, at least annually. The panel also emphasized individualized risk-benefit assessment, patient preferences, functioning, and the consequences of changing one medication within a larger regimen. ([jamanetwork.com](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2845497))
That sounds straightforward. It is not.
The harder question is what a real review must reconstruct. Not just what is being taken now, but the chain of decisions that produced the current regimen.
The refill is not the evidence
Long-term treatment can acquire an appearance of inevitability. A medication was started during a difficult period. It may have helped, partly helped, caused problems that were tolerated, or simply remained in place while life moved on.
Years later, the original target can be blurry. Was the medication started for panic, insomnia, low mood, agitation, concentration, a crisis, an uncertain diagnosis, or a side effect from something else? Was there a meaningful response? Did the dose change? Did other medications arrive later to address symptoms that began after the first one?
Without that history, “stable” can mean several very different things.
It may mean the medication remains useful. It may mean a person has recovered while taking it, but nobody knows how much credit belongs to the medication, time, changed circumstances, or other care. It may mean adverse effects have become normalized. It may mean the prospect of change feels risky because prior changes were difficult.
None of those possibilities settles the decision. But they are not interchangeable.
Continuation deserves the same scrutiny as change
Medication decisions are often framed as though changing treatment requires a reason while continuing does not. I keep coming back to the flaw in that logic.
Continuation is also a decision. It has possible benefits, costs, and uncertainties. So does reduction or discontinuation. The relevant comparison is not medication versus no medication in the abstract. It is this medication, at this point in a person’s history, compared with realistic alternatives and the risks of altering a system that may have adapted over time.
That is why a good review asks two parallel questions:
- What is this medication plausibly doing now?
- What burdens or risks might continued exposure carry now?
Burden can include side effects, adverse effects, practical inconvenience, financial cost, interactions, sexual effects, sleep changes, metabolic concerns, cognitive complaints, emotional blunting, or the complexity of managing several medications at once. It can also include uncertainty itself, especially when nobody can clearly state the treatment target.
At the same time, benefit should not be dismissed simply because it is hard to measure. A medication may be associated with fewer episodes, greater functioning, better sleep, or a reduction in symptoms that were previously severe. The fact that a benefit cannot be proven with certainty in one individual does not make it imaginary.
Good judgment requires holding both ideas at once.
When symptoms change, names matter
The most consequential errors often happen after a medication change, when familiar symptoms return.
Anxiety, low mood, insomnia, panic, agitation, or emotional volatility may be called relapse almost automatically. But a label is not an explanation.
Depending on the medication, timing, pattern, accompanying symptoms, prior history, and course over time, post-change symptoms might reflect withdrawal, rebound, return of prior symptoms, recurrence of an underlying condition, a medication interaction, a life event, or more than one of these at once.
Physical dependence is relevant here. Long-term exposure can produce physiological adaptation without addiction or compulsive drug-seeking. And withdrawal symptoms after a reduction do not, by themselves, prove that a medication must be continued indefinitely. They also do not prove that the medication was inappropriate in the first place.
Here’s the part worth looking at: uncertainty is not a reason to force a conclusion. It is a reason to improve observation.
The recent consensus statement acknowledges the need to consider withdrawal reactions and rebound syndromes when evaluating medication changes. It also makes clear that its recommendations are a conceptual framework, not a one-size-fits-all standard of care. The authors note a need for stronger longitudinal discontinuation research. ([jamanetwork.com](https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2845497))
A review should produce a clearer record
A useful medication review leaves behind more than a renewed prescription. It should make the working logic visible.
What was the original problem? What changed after the medication was introduced or adjusted? What benefits are still considered meaningful? What adverse effects or tradeoffs have emerged? Which symptoms existed before treatment, and which appeared after it? What would count as evidence that the current plan is working, no longer working, or creating more burden than benefit?
This is especially important in polypharmacy. If several medications changed across several years, assigning cause becomes difficult. If multiple medications are changed at once, interpretation becomes even harder. The desire for a clean answer can create a messy decision.
The goal is not to turn every annual review into a referendum on medication. Nor is it to preserve treatment by default because the past is difficult to reconstruct.
The goal is decision integrity: making sure the current plan rests on a current rationale, not on inertia, fear, ideology, or an incomplete story.
That is the question I would want a medication review to answer: What do we believe this treatment is doing now, what is that belief based on, and what important uncertainty remains?
Written for Dr. Teralyn Sell, PhD
Psychology · Brain Health · Human Behavior